Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKesson
AstraZeneca
McKinsey
Merck
Moodys

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Litigation Details for Apotex, Inc. v. UCB, Inc. (S.D. Fla. 2012)

See Plans and Pricing

« Back to Dashboard

Apotex, Inc. v. UCB, Inc. (S.D. Fla. 2012)

Docket   Start Trial Date Filed 2012-04-20
Court District Court, S.D. Florida Date Terminated 2013-09-19
Cause 35:0271 Patent Infringement Assigned To Donald M. Middlebrooks
Jury Demand Defendant Referred To Magistrate Judge Dave Lee Bran
Parties APOTEX CORP.; APOTEX, INC.; KREMERS URBAN PHARMACEUTICALS, INC.; PADDOCK LABORATORIES, LLC; PERRIGO COMPANY; SCHWARZ PHARMA INC.; UCB, INC.
Patents 4,344,949; 4,374,829; 4,743,450
Attorneys Adam R. Gahtan; Amit Thakore; Brian J. Sodikoff; Christopher B. Ferenc; Christopher J. Glancy; Christopher K. Leach; Craig M. Kuchii; David R. Van Buskirk; Dennis C. Lee; Dimitrios Drivas; Elese E. Hanson; Eric C. Cohen; Eric David Isicoff; Julia L. Kasper; L. Scott Beall; Laura Moran; Maria Josefa Beguiristain; Martin S. Masar , III; Matthew Scott Nelles; Michael A. Dorfman; Robert Burton Breisblatt; Suresh B. Pillai
Link to Docket External link to docket
Small Molecule Drugs cited in Apotex, Inc. v. UCB, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Apotex, Inc. v. UCB, Inc. (S.D. Fla. 2012)

Date Filed Document No. Description Snippet Link To Document
2013-07-19 192 Exhibit B - Cima Opening Report excerpts light of the ‘450 patent alone or in combination with U.S. Patent No. 4,344,949. 40. On September… C. The ‘556 Patent Prosecution History 38. In reviewing the ’556 patent prosecution history…ATTORNEYS’ EYES ONLY 37. Claim 12 of the ‘556 patent, depends on, inter alia, Claims 1 and 8, and encompasses…this report. 39. On March 21, 2002, the patent examiner rejected Claims 1-18 of the application…September 18, 2002, the patent prosecutor, Neil Hughes, filed a response to the examiner’s rejections, External link to document
2013-07-20 197 Exhibit A - UCB's 282 Notice AI-MOEX0203621-25] 3. Hoefle et al., U.S. Patent No. 4,344,949, entitled “Substituted Acyl Derivatives …hereby identify certain persons, publications, patents, and other prior art to be relied upon as showing…obviousness or the state of the art relating to the patent-in-suit. Defendants affirmatively state…identity of certain persons, publications, patents, and other prior art within the ambit of 35 U.S.C… of those documents, and the publications, patents, and identification of persons within the ambit External link to document
2013-09-06 222 expresslyincorporatescompoundsaslistedinU.S.PatentNo.4,344,949(the11'949Patenf'), whichdisclosesmoexipril…9556 Patent,butalso thathe was aware ofits materiality to the patentability ofthe '556 Patent. … The 450 Patent On M ay 10th, 1988,United States Patent No. 4,743, …manufacturing the '450 Patent's invention. Each ofthe '450 Patent's ExamplesA through…23(Chyall)). This patent was disclosed during the '556 Patent prosecution. But what was not External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Johnson and Johnson
Dow
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.